| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Differentially expressed in AML and evaluated as a candidate biomarker for distinguishing AML patients from healthy donor controls. |
| Molecular mechanism: |
Not experimentally specified for this circRNA; the study discussed possible effects on parental gene transcription or competitive binding to target microRNAs. |
| Biological pathway or process: |
not specified |
| Detected method: |
Q
M
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
circ-CSMD2 distinguished AML patients from healthy donor controls, but was not correlated with risk stratification, complete remission, EFS or OS. |
| Description: |
circ-CSMD2 was validated by RT-qPCR as up-regulated in AML BMMCs. It showed diagnostic potential for distinguishing AML patients from healthy controls, but no significant survival association was reported. |
| Confidence score: |
0.636 |